Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial
Intravaginal estradiol therapy (10ug) during adjuvant letrozole resulted in transient increases in systemic E2 levels among early BC patients with VVA. Highly sensitive LC-MS/MS is a promising method for monitoring E2 levels during aromatase inhibitor (AI) therapy.
Authors
- Heli Lyytinen
- Aila Tiitinen (ORCID: https://orcid.org/0000-0003-3088-5594)
- Hanna Savolainen‐Peltonen (ORCID: https://orcid.org/0000-0003-4139-669X)
- Mária Faltinová (ORCID: https://orcid.org/0000-0002-0749-2955)
- Esa Hämäläinen (ORCID: https://orcid.org/0000-0002-4614-4347)
- Johanna Mattson (ORCID: https://orcid.org/0000-0002-9719-9110)
- Leena Vehmanen (ORCID: https://orcid.org/0000-0003-0123-1313)
- Mikko Haanpää
- Anni Virtanen (ORCID: https://orcid.org/0000-0002-7467-8434)
Institutions
- University of Helsinki (FI)
- University of Eastern Finland (FI)
- Helsinki University Hospital (FI)
- Hospital District of Helsinki and Uusimaa (FI)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1007/s10549-024-07564-8
- Citations
- 4
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 2.20
Funders
- Helsingin Yliopisto